---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237374067.md"
description: "Sinobioway Medicine: The Tianjin Municipal Medical Products Administration has decided to implement risk control measures to suspend production and sales of Tianjin Sinobioway Biopharmaceutical Co., Ltd. The company's main business has been severely affected due to the suspension of production at Tianjin Sinobioway"
datetime: "2025-04-24T11:58:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237374067.md)
  - [en](https://longbridge.com/en/news/237374067.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237374067.md)
generator: "portal-rs"
---

# 

Sinobioway Medicine: The Tianjin Municipal Medical Products Administration has decided to implement risk control measures to suspend production and sales of Tianjin Sinobioway Biopharmaceutical Co., Ltd. The company's main business has been severely affected due to the suspension of production at Tianjin Sinobioway

### Related Stocks

- [002581.CN](https://longbridge.com/en/quote/002581.CN.md)
- [399441.CN](https://longbridge.com/en/quote/399441.CN.md)

## Related News & Research

- [VERAXA Biotech (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology](https://longbridge.com/en/news/297353256.md)
- [Livzon MABPharm wins China approval for Lecankitug psoriasis injection](https://longbridge.com/en/news/297167246.md)
- [ReVolve Renewable Power secures MXN 450 million project financing facility with Banco Multiva](https://longbridge.com/en/news/297172638.md)
- [ByHeart Says FDA Confirms Review Of ByHeart's Root Cause Investigation And Action Plan](https://longbridge.com/en/news/297358769.md)
- [Simpar publishes CS Infra investor presentation factsheet](https://longbridge.com/en/news/297182611.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**